Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
OBJECTIVE
The purpose of this study was to determine if early luteinizing potential in gonadotropin releasing hormone agonist (GnRH-a)-suppressed/human menopausal gonadotropin (hMG)-stimulated IVF cycles is predictive of cycle outcome.


METHODS
The study was a prospective evaluation of 41 women beginning a GnRH-a-suppressed/hMG-stimulated IVF cycle.


METHODS
The in vitro fertilization program of a tertiary care institution was the study setting.


METHODS
The main outcome measures were (1) estradiol (E2) and progesterone (P) levels on the day of human chorionic gonadotropin (hCG) administration and the following day and (2) the ovarian response to ovulation induction and clinical outcome.


RESULTS
Ten of the 41 women achieved a clinical pregnancy (24.4%). There was no significant difference in progesterone (P) levels on the day of or the day following hCG administration between the pregnant and the nonpregnant groups. Both groups exhibited a significant rise in P level in response to hCG. There was no significant difference in E2 levels on the day of hCG between the two groups. The serum E2 did not rise significantly in response to hCG in either group. Patients who became pregnant had significantly more oocytes retrieved, fertilized, cleaved, and transferred.


CONCLUSIONS
Clinical response and outcome in GnRH-a-suppressed/hMG-stimulated IVF cycles are not predicted by early luteinizing potential as indicated by the response of E2 or P to hCG.
Penzias
A S
AS
Yale University School of Medicine, Department of Obstetrics and Gynecology, New Haven, Connecticut 06510.
Shamma
F N
FN
Gutmann
J N
JN
Seifer
D B
DB
DeCherney
A H
AH
Lavy
G
G
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects*; D008596:Menotropins / Q000494:pharmacology*; D010060:Ovulation / Q000502:physiology*; D010062:Ovulation Induction / Q000379:methods; D011237:Predictive Value of Tests; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D006063:Chorionic Gonadotropin; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; C019176:Tryptal; D008596:Menotropins